The Motley Fool has a disclosure policy.Ĭopyright © 1995 - 2013 The Motley Fool, LLC. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days. The Motley Fool has no position in any of the stocks mentioned. The article Study Boosts Prospects for Pfizer's Chantix originally appeared on .įool contributor Rich Smith has no position in any stocks mentioned. Romano was quoted as saying: "These new data show that, for some adult smokers who had previously taken CHANTIX but either did not quit smoking or relapsed after quitting, another quit attempt with CHANTIX may be fruitful." Summarizing the findings, Pfizer senior vice president and medicines development group head Dr. Scores ranging from 0-13 would be considered low stress. The PSS-10 uses a 5-point scale (0 - never, 1 almost never, 2 once in a while, 3 often, 4 very often). Safety and tolerability of the drug were similarly found to be "consistent with previous studies," with the most commonly reported side effects being nausea, abnormal dreams, and headaches. Stress levels in the last 30 days will be measured using the 10-item Perceived Stress Scale (PSS-10). Translation: It works just as well the second time around. consistent with findings seen in other Chantix clinical trials in smokes who had not been previously treated with Chantix." Over the course of 12 weeks of treatment, smokers who had used Chantix before and failed to quit, or had quit but subsequently relapsed, were found to benefit from Chantix at "efficacy rates. On Thursday, Pfizer announced the results of a study of the safety and effectiveness of its Chantix smoking-cessation drug on relapsed smokers.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |